Periprocedural bridging anticoagulation: current perspectives
Review published in American journal of therapeutics (2011)
Abstract
Perioperative management of patients on chronic anticoagulant use involves balancing individual risk for thromboembolism and bleeding. Discontinuation of antithrombotic therapy can place patients at increased risk of thromboembolic complications, whereas continuing antithrombotic therapy can increase procedure-related bleeding risk. Temporary perioperative substitution of low-molecular weight heparin or unfractionated heparin in place of warfarin, "the bridge therapy" is often used in the periprocedural period, but the indications and timing of this is still uncertain. This review addresses the risk stratification of patients according to thromboembolic risk, indications, timing, and duration, and a practical approach to bridge therapy.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
This review addresses periprocedural bridging anticoagulation, in which heparin temporarily replaces warfarin, covering risk stratification for thromboembolism versus bleeding along with indications, timing, duration of bridge therapy, and a practical management approach.
Context
This review addresses the risk stratification, indications, timing, and practical approaches to periprocedural bridging anticoagulation, which involves substituting heparin for warfarin temporarily. It focuses on balancing the risks of thromboembolism and procedure-related bleeding during invasive procedures. The abstract focuses strictly on conventional medical management with warfarin and heparin. No leeches, hirudin, or related therapies are mentioned or implied in the text.
Citation
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026